Nemolizumab-Ilto
Common brands: Nemluvio, Dupixent, Vitamin D, Allergy Relief, Allergy Nasal
Top reporter: Galderma Laboratories, L.P.
Interleukin-31 Receptor alpha Antagonist [EPC]Interleukin-4 Receptor alpha Antagonist [EPC]Corticosteroid [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Provitamin D2 Compound [EPC]
9,893
Total Reports
9,880
Serious Reports
80
Death Reports
30
Reported Reactions
Death Report Ratio: Low (0.81%)
Patient Demographics
Reported Adverse Reactions (30)
Side effects reported in FDA adverse event reports for Nemolizumab-Ilto.
| # | Reaction | Reports | % of Total |
|---|---|---|---|
| 1 | PRODUCT DOSE OMISSION ISSUE | 3,056 | |
| 2 | DEVICE MALFUNCTION | 1,634 | |
| 3 | INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 1,431 | |
| 4 | INCORRECT DOSE ADMINISTERED | 1,036 | |
| 5 | PRURITUS | 994 | |
| 6 | RASH | 651 | |
| 7 | DRUG INEFFECTIVE | 536 | |
| 8 | HEADACHE | 345 | |
| 9 | DERMATITIS ATOPIC | 334 | |
| 10 | DEVICE LEAKAGE | 291 | |
| 11 | ECZEMA | 262 | |
| 12 | DEVICE USE ISSUE | 250 | |
| 13 | DRY SKIN | 223 | |
| 14 | NEURODERMATITIS | 222 | |
| 15 | ARTHRALGIA | 216 | |
| 16 | ERYTHEMA | 205 | |
| 17 | SKIN EXFOLIATION | 183 | |
| 18 | INTENTIONAL PRODUCT USE ISSUE | 172 | |
| 19 | URTICARIA | 156 | |
| 20 | INJECTION SITE HAEMORRHAGE | 147 | |
| 21 | RASH PAPULAR | 147 | |
| 22 | HYPERSENSITIVITY | 146 | |
| 23 | DEVICE USE ERROR | 132 | |
| 24 | CONDITION AGGRAVATED | 118 | |
| 25 | PAIN | 116 | |
| 26 | MYALGIA | 105 | |
| 27 | INJECTION SITE PAIN | 101 | |
| 28 | OFF LABEL USE | 89 | |
| 29 | BLISTER | 85 | |
| 30 | SKIN DISCOLOURATION | 83 |
Important Disclaimer
FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.